This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 19, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 33 million shares of its common stock, offered at a price of
$1.00 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be
$33 million. The offering is expected to close on or about
July 24, 2012, subject to customary closing conditions. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 4.95 million shares of common stock to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for general corporate purposes.
Piper Jaffray & Co. and Leerink Swann LLC are acting as joint book-running managers in the offering. Canaccord Genuity is acting as lead manager in the offering. Summer Street Research Partners is acting as co-manager in the offering.
The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website at
http://www.sec.gov. Copies of the final prospectus supplement relating to these securities, when available, may be obtained from
Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at
firstname.lastname@example.org, or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110 or by telephone at 800-808-7525 or by email at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.